Regulatory Questionnaire

EMA List of Questions – Type II Variation (ID001)

Procedure: EMEA/H/C/005432/II/0023 | Response due: 2025-12-11

The Regulatory Questionnaire profile defines a structured, machine-readable format for regulatory questions. This resource enables automated routing, tracking, and response management while preserving rich formatting and traceability to the Common Technical Document (CTD) structure.

Participants & Contacts
SENDER (REGULATOR)
European Medicines Agency
Scientific and Regulatory Management
Human Medicines Evaluation Division
jane.doe@ema.europa.eu
RECIPIENT (MAH)
SynthPharma AG
Global Regulatory Strategy
Basel, Switzerland
john.doe@synthpharma.example
1.0 Administrative Information
CTD Ref: 1.1 Application Form ID: 1
1
Is the fee for the Type II variation fully paid and documented?

See EMA Fee Guidance for payment confirmation requirements.

CTD Ref: 1.1 Application Form ID: 2
2
Are all required metadata fields in the application form complete?
  • Marketing Authorisation Holder
  • Product Name (INN)
  • Procedure Number
  • Submission Date
1.3 Product Information
CTD Ref: 1.3.1 SmPC, Labelling and Package Leaflet ID: 3
3
Do the updated storage conditions (2–8°C for 36 months) require additional patient guidance?

Current ePI states: “Store in a refrigerator (2°C – 8°C). Do not freeze.”

CTD Ref: 1.3.1 SmPC, Labelling and Package Leaflet ID: 4
4
Is the patient leaflet revised to clarify the extended shelf life?

“Shelf life after first opening: 36 months when stored at 2–8°C”

CTD Ref: 1.3.1 SmPC, Labelling and Package Leaflet ID: 5
5
Is the updated ePI text sufficiently clear for all EU languages?
Language Status
English Approved
French Under Review
German Pending
3.2.P.8 Stability
CTD Ref: 3.2.P.8.1 Stability Summary and Conclusion ID: 6
6
Are there any new stability studies conducted?
  • Include protocol deviations if any.
  • Reference: ICH Q1A(R2)
CTD Ref: 3.2.P.8.1 Stability Summary and Conclusion ID: 7
7
Does the data support all intended climatic zones?

Confirm coverage for Zone IVb (30°C/75% RH) per WHO TRS 1010

3.2.P.5 Control of Drug Product
CTD Ref: 3.2.P.5.2 Analytical Procedures ID: 8
8
Are the test methods used consistent with previous submissions?

If changed: justify and provide validation data per ICH Q2(R1).

CTD Ref: 3.2.P.5.4 Impurities ID: 9
9
Are there any new degradation products identified?

Threshold: >0.10% per ICH Q3B(R2)

3.2.P.7 Container Closure System
CTD Ref: 3.2.P.7 Container Closure ID: 10
10
Any changes in the packaging configuration during stability?
[Figure 1: Cross-section of proposed aluminum/aluminum blister pack]
Original New
PVC/PVDC Blister Alu/Alu Blister